- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ADAC's Lowe passes CEO title to Eckert
ADAC Laboratories has added CEO to Andrew Eckert's list of titles, which already includes president and COO. Giving up the CEO mantle is David Lowe, who will remain chairman of the Milpitas, CA, nuclear medicine vendor. ADAC said the transition was part
ADAC Laboratories has added CEO to Andrew Eckert's list of titles, which already includes president and COO. Giving up the CEO mantle is David Lowe, who will remain chairman of the Milpitas, CA, nuclear medicine vendor. ADAC said the transition was part of a long-planned management development strategy, and that Lowe will continue to develop the company's strategic and operating plans.
In other ADAC news, the company signed an agreement to provide multivendor service and support of gamma cameras to customers in the asset management program of independent service organization COHR. The agreement will add over 75 gamma cameras to ADAC's multivendor service effort, which ADAC began in 1995 with the acquisition of JD Technical Services (SCAN 12/13/95).
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
